- Home
- / Verona Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Verona Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$33.7
2024-10-29
Market Capitalization
$2.7 B
2024-10-29
Revenue
$42.3 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 40.0M | 458.0K | 42.3M | ||||
| Cost of goods sold | 346.0K | 1.4M | |||||
| Gross profit | 40.0M | 112.0K | 40.9M | ||||
| Gross profit margin, % | 96.8% | ||||||
| Operating expense total | 25.5M | 40.2M | 73.4M | 112.7M | 75.2M | 66.9M | 194.3M |
| Depreciation and amortization | 98.0K | 504.0K | 912.0K | 629.0K | 636.0K | 677.0K | 1.1M |
| EBITDA | (25.5M) | (40.2M) | (73.4M) | (72.7M) | (75.1M) | (66.9M) | (153.4M) |
| EBITDA margin, % | -362.8% | ||||||
| EBIT | (25.6M) | (40.7M) | (66.0M) | (57.7M) | (66.9M) | (66.5M) | (154.5M) |
| EBIT margin, % | -365.5% | ||||||
| Interest income | 861.0K | 754.0K | 121.0K | 14.0K | 2.8M | 12.8M | 15.3M |
| Interest expense | 106.0K | 169.0K | 340.0K | 521.0K | 2.1M | 23.5M | |
| Pre tax profit | (24.1M) | (39.2M) | (65.0M) | (55.6M) | (68.4M) | (53.9M) | (163.0M) |
| Income tax expense | (4.2M) | (7.3M) | 146.0K | (18.0K) | 253.0K | 474.0K | 10.3M |
| Net Income | (19.9M) | (31.9M) | (65.1M) | (55.6M) | (68.7M) | (54.4M) | (173.2M) |